2441 related articles for article (PubMed ID: 22801398)
41. Novel oral anticoagulants in non-valvular atrial fibrillation.
Potpara TS; Lip GY
Best Pract Res Clin Haematol; 2013 Jun; 26(2):115-29. PubMed ID: 23953900
[TBL] [Abstract][Full Text] [Related]
42. [Anticoagulant therapy in stroke patients].
Kraglund KL; Husted SE; Modrau B; Grove EL
Ugeskr Laeger; 2013 Jan; 175(5):265-8. PubMed ID: 23369327
[TBL] [Abstract][Full Text] [Related]
43. Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
Int J Clin Pharmacol Ther; 2015 Mar; 53(3):211-9. PubMed ID: 25295718
[TBL] [Abstract][Full Text] [Related]
44. [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Rudakova AV; Tatarskiĭ BA
Kardiologiia; 2014; 54(7):43-52. PubMed ID: 25177813
[TBL] [Abstract][Full Text] [Related]
45. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
Steiner T; Böhm M; Dichgans M; Diener HC; Ell C; Endres M; Epple C; Grond M; Laufs U; Nickenig G; Riess H; Röther J; Schellinger PD; Spannagl M; Veltkamp R
Clin Res Cardiol; 2013 Jun; 102(6):399-412. PubMed ID: 23669868
[TBL] [Abstract][Full Text] [Related]
46. Direct oral anticoagulants in atrial fibrillation.
Noll G; Noll S; Hürlimann D
Semin Hematol; 2014 Apr; 51(2):139-46. PubMed ID: 24861798
[TBL] [Abstract][Full Text] [Related]
47. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
Akwaa F; Spyropoulos AC
Hosp Pract (1995); 2013 Feb; 41(1):8-18. PubMed ID: 23466963
[TBL] [Abstract][Full Text] [Related]
48. [New anticoagulants in patients with atrial fibrillation].
Diener HC; Weber R
MMW Fortschr Med; 2013 May; 155(8):55-6, 58. PubMed ID: 24437140
[No Abstract] [Full Text] [Related]
49. New oral anticoagulants for non-valvular atrial fibrillation--safety issues.
Barry M
Ir Med J; 2013 Mar; 106(3):69. PubMed ID: 23951972
[No Abstract] [Full Text] [Related]
50. Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
Destephan C; Waller AH; Patel RJ; Dhruvakumar S; Mazza V; Gerula C; Maher J; Kaluski E
Minerva Cardioangiol; 2012 Aug; 60(4):425-31. PubMed ID: 22858920
[TBL] [Abstract][Full Text] [Related]
51. [Gastrointestinal bleeding under treatment with new oral anticoagulants].
Konturek P; Hess T
MMW Fortschr Med; 2014 Feb; 156(2):50-2. PubMed ID: 24934056
[No Abstract] [Full Text] [Related]
52. [New oral anticoagulants for atrial fibrillation: a neurologist's view].
van Dijk EJ; Koudstaal PJ; Roos YB; Brouwers PJ; Kappelle LJ
Ned Tijdschr Geneeskd; 2012; 156(39):A5283. PubMed ID: 23009824
[TBL] [Abstract][Full Text] [Related]
53. Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
Levy JH
Clin Lab Med; 2014 Sep; 34(3):443-52. PubMed ID: 25168936
[TBL] [Abstract][Full Text] [Related]
54. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
Chan KE; Edelman ER; Wenger JB; Thadhani RI; Maddux FW
Circulation; 2015 Mar; 131(11):972-9. PubMed ID: 25595139
[TBL] [Abstract][Full Text] [Related]
55. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2012; 15(4):776-85. PubMed ID: 22449118
[TBL] [Abstract][Full Text] [Related]
56. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
Gong IY; Kim RB
Can J Cardiol; 2013 Jul; 29(7 Suppl):S24-33. PubMed ID: 23790595
[TBL] [Abstract][Full Text] [Related]
57. New alternative anticoagulants in atrial fibrillation: the move beyond warfarin.
Bhimani AA; Hong M
Rev Recent Clin Trials; 2013 Jun; 8(2):78-85. PubMed ID: 23859143
[TBL] [Abstract][Full Text] [Related]
58. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
[TBL] [Abstract][Full Text] [Related]
59. Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
Morales-Vidal S; Schneck MJ; Flaster M; Biller J
Expert Rev Neurother; 2012 Feb; 12(2):179-89; quiz 190. PubMed ID: 22288673
[TBL] [Abstract][Full Text] [Related]
60. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Koziński M; Obońska K; Kubica A; Navarese EP; Kubica J
Kardiol Pol; 2012; 70(10):1053-60. PubMed ID: 23080100
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
